COPD Alters Immune Cell Composition and Immune Checkpoint Inhibitor Efficacy in NSCLC.

CONCLUSIONS: In patients with COPD, Th1 cells populations were expanded in both lungs and tumors microenvironments, and the presence of COPD was associated with longer progression free interval in patients treated with ICIs. This has implications for understanding the immune mediators of COPD and for developing novel therapies for NSCLC.
PMID: 28934595 [PubMed - as supplied by publisher]

Source: American Journal of Respiratory and Critical Care Medicine - September 21, 2017 Category: Respiratory Medicine Authors: Mark NM, Kargl J, Busch SE, Yang GHY, Metz HE, Zhang H, Hubbard JJ, Pipavath SNJ, Madtes DK, Houghton AM Tags: Am J Respir Crit Care Med Source Type: research